Drug intelligence / Profile preview

CMPD1

Development stage: Preclinical
Modality: Small Molecules
Administration: Subcutaneous, Intratumoral

Overview

CMPD1 is a selective and non-ATP-competitive small molecule that acts as an inhibitor of p38 MAPK-mediated MK2 phosphorylation. Subsequent research has also identified it as a tubulin polymerization inhibitor. It has demonstrated cytotoxic activity in various cancer cell lines, including glioblastoma and breast cancer, by inducing mitotic arrest and apoptosis. CMPD1 is primarily used as a research chemical to study the p38-MK2 pathway and microtubule dynamics.

Other names: 2'-Fluoro-N-(4-hydroxyphenyl)-[1,1'-biphenyl]-4-butanamideMK2 InhibitorMK-2 InhibitorMK 2 Inhibitor

Targets

MK2 (Mitogen-activated protein kinase-activated protein kinase 2)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on CMPD1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMPD1.

Explore the full profile